This document relates to an infusion pump system, such as a portable infusion pump system for dispensing a medicine.
Pump systems are commonly used to deliver one or more fluids to a targeted individual. For example, a medical infusion pump system may be used to deliver a medicine to a patient as part of a medical treatment. The medicine that is delivered by the infusion pump system can depend on the condition of the patient and the desired treatment plan. For example, infusion pump systems have been used to deliver insulin to the vasculature of diabetes patients so as to regulate blood-glucose levels.
Infusion pump systems often need to deliver medicine in accurately controlled dosages. Over-dosages and under-dosages of medicine can be detrimental to patients. For example, an infusion pump system that delivers an over-dosage or under-dosage of insulin to a diabetes patient can significantly affect the blood-glucose level of the patient.
Some embodiments of an infusion pump system include a pump device with a drive system that is configured to attach with a medicine cartridge in manner that reduces the likelihood of dosage inaccuracies. For example, in particular embodiments, the drive system of the pump device can be equipped with a plunger engagement device that is configured to mechanically anchor into a plunger of the medicine cartridge, and then to bias the plunger of the medicine cartridge in a direction toward a piston rod of the drive system. In such circumstances, the plunger engagement device can reduce or eliminate a gap that might otherwise be present between a rearward face of the plunger and the forward face of the pushing element of the drive system, and can and thereafter retaining the plunger in a predictable position relative to the piston rod during operation of the pump device.
Particular embodiments described herein include a portable infusion pump system. The system may include a pump housing that defines a space to receive a medicine cartridge, and a drive system to dispense medicine from the medicine cartridge when the medicine cartridge is received by the pump housing. The drive system may include a piston rod configured to forwardly advance toward the medicine cartridge when the medicine cartridge is received by the pump housing, and a plunger engagement device coupled to the piston rod. The plunger engagement device may include at least one penetration member to couple the drive system to a plunger of the medicine cartridge. Optionally, the plunger engagement device may also include a spring adjustable from a deactivated condition to an activated condition in which a spring force of the spring biases the plunger towards the piston rod.
In other embodiments, a portable infusion pump system may include a pump housing that defines a space to receive a medicine cartridge, a drive system to dispense medicine from the medicine cartridge when the medicine cartridge is received by the pump housing, and a controller device. Optionally, the drive system may include a piston rod configured to forwardly advance toward the medicine cartridge when the medicine cartridge is received by the pump housing, and a plunger engagement device coupled to the piston rod. Optionally, the controller device may be in the form of a device that is removably attachable to the pump housing so as to electrically connect with a pump device comprising the pump housing and the drive system. The controller device may house control circuitry configured to communicate with the drive system positioned in the pump housing to control dispensation of the medicine from the pump device. The plunger engagement device may include a piston hub coupled to the piston rod, a retention plate installed about the piston hub, and at least one penetration member supported by the retention plate to couple the drive system to a plunger of the medicine cartridge. Also, the plunger engagement device may optionally include a spring seated between the piston hub and the retention plate. The spring may be adjustable from a deactivated condition to an activated condition in which a spring force of the spring biases the retention plate away from the piston hub to pull the plunger against a surface of the piston hub.
In some embodiments of a portable infusion pump system, the system may include a pump housing and a drive system that includes a plunger engagement device. The pump housing may define a space to receive a medicine cartridge. The drive system may be configured to dispense medicine from the medicine cartridge when the medicine cartridge is received by the pump housing. The drive system may include a piston rod configured to forwardly advance toward the medicine cartridge when the medicine cartridge is received by the pump housing, and the plunger engagement device coupled to the piston rod. The plunger engagement device may include at least one means for penetrating a plunger of the medicine cartridge, and a means for biasing the plunger towards the piston rod by adjusting from a deactivated condition to an activated condition. Optionally, the means for biasing may include a spring device.
Particular embodiments described herein include a method of operating an infusion pump device. The method may include receiving a medicine cartridge in an internal space of a housing of a pump device. A plunger engagement device may be positioned in the internal space. The method may also include penetrating a plunger of the medicine cartridge with at least one penetration member of the plunger engagement device. Optionally, the method may further include, after penetrating the plunger with said at least one penetration member, applying a spring bias to the plunger to bias the plunger towards a component of a drive system of the pump device.
Some or all of the embodiments described herein may provide one or more of the following advantages. First, some embodiments of the drive system of the pump device can accurately and incrementally dispense fluid from the pump device in a controlled manner. For example, the drive system housed within the pump device can include a plunger engagement device (positioned at the leading end of the piston rod) that attaches to a plunger of a medicine cartridge installed into the pump device, and plunger engagement device can be configured to reduce or eliminate any gap between the piston rod and the plunger (e.g., a gap that is a potential source of inaccuracy in the dispensation of the medicine). Accordingly, in particular circumstances, the plunger engagement device may reduce the likelihood of dosage inaccuracy of the infusion pump device by inhibiting inadvertent movement of the plunger relative to the piston rod.
Second, in particular embodiments, the pump device may be removably attached to a controller device so that a user can readily monitor infusion pump operation by simply viewing a user interface that is releasably connected to the pump device.
Third, some embodiments of the infusion pump system may be configured to be portable, wearable, and (in some circumstances) concealable. For example, a user can conveniently wear the infusion pump system on the user's skin under clothing or can carry the pump device in the user's pocket (or other portable location) while receiving the medicine dispensed from the pump device.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
Referring to
In some embodiments, the controller device 200 communicates with the pump device 100 to control the operation of the drive system. When the controller device 200, the pump device 100 (including the cap device 130), and the fluid cartridge 120 are assembled together, the user can (in some embodiments) conveniently wear the infusion pump system 10 on the user's skin under clothing, in a pouch clipped at the waist (e.g., similar to a cell phone pouch), or in the user's pocket while receiving the fluid dispensed from the pump device 100. Optionally, the controller device 200 may be configured as a reusable component that provides electronics and a user interface to control the operation of the pump device 100. In such circumstances, the pump device 100 can be a disposable component that is disposed of after a single use. For example, the pump device 100 can be a “one time use” component that is thrown away after the fluid cartridge 120 therein is exhausted. Thereafter, the user can removably attach a new pump device (having a new fluid cartridge) to the reusable controller device 200 for the dispensation of fluid from a new fluid cartridge. Accordingly, the user is permitted to reuse the controller device 200 (which may include complex or valuable electronics, as well as a rechargeable battery) while disposing of the relatively low-cost pump device 100 after each use. Such a pump system 10 can provide enhanced user safety as a new pump device (and drive system therein) is employed with each new fluid cartridge.
Briefly, in use, the pump device 100 is configured to removably attach to the controller device 200 in a manner that provides a secure fitting, an overall compact size, and a reliable electrical connection that is resistant to water migration. For example, the controller device 200 can include a housing 210 having a number of features that mate with complementary features of the pump housing 110. In such circumstances, the controller device 200 can removably attach with the pump device 100 in a generally side-by-side configuration. The compact size permits the infusion pump system 10 to be discrete and portable (as described below in connection with
The pump system 10 can be a medical infusion pump system that is configured to controllably dispense a medicine from the fluid cartridge 120. As such, the fluid 126 contained in the fluid cartridge 120 can include a medicine to be infused into the tissue or vasculature of a targeted individual, such as a human or animal patient. For example, the pump device 100 can be adapted to receive a fluid cartridge 120 in the form of a carpule that is preloaded with insulin or another medicine for use in the treatment of Diabetes (e.g., Byetta®, Symlin®, or others). Such a fluid cartridge 120 may be supplied, for example, by Eli Lilly and Co. of Indianapolis, Ind. Other examples of medicines that can be contained in the fluid cartridge 120 include: pain relief drugs, hormone therapy, blood pressure treatments, anti-emetics, osteoporosis treatments, or other injectable medicines. The fluid cartridge 120 may have other configurations. For example, the fluid cartridge 120 may comprise a reservoir that is integral with the pump housing 110 (e.g., the fluid cartridge 120 can be defined by one or more walls of the pump housing 110 that surround a plunger to define a reservoir in which the medicine is injected or otherwise received).
In some embodiments, the pump device 100 can include one or more structures that interfere with the removal of the fluid cartridge 120 after the fluid cartridge 120 is inserted into the cavity 116. For example, the pump housing 110 can include one or more retainer wings (not shown in
Still referring to
In some embodiments, a longitudinal force 140 is applied to the fluid cartridge 120 as various components of the pump device 100 are prepared for use by a user. For example, in some embodiments, the longitudinal force 140 may be applied by a user's fingers as the fluid cartridge 120 is inserted into the pump housing 110 (e.g., the user may press the fluid cartridge 120 longitudinally into the cavity). In some embodiments, the longitudinal force 140 may be applied during engagement of the cap device 130 with the housing 110. For example, one or more actions by a user to engage the cap device 130 with the housing 110 (e.g., pressing down on a portion of the cap device 130 or rotating a portion of the cap device 130) may cause a shoulder surface 136 of the cap device 130 to bear against a flange surface 129 of the fluid cartridge 120. In some embodiments, the longitudinal force 140 can be applied in stages. For example, a first stage of the longitudinal force 140 may be applied from the user's fingers as the fluid cartridge 120 is inserted into the pump housing 110, and a second stage of the longitudinal force 140 may be applied from the cap device 130 pressing upon the cartridge 120 during engagement of the cap device 130.
Still referring to
When the pump device 100 and the controller device 200 are attached and thereby electrically connected, the controller device 200 communicates electronic control signals via a hardwire-connection (e.g., electrical contacts or the like) to the drive system or other components of the pump device 100. In response to the electrical control signals from the controller device 200, the drive system of the pump device 100 causes medicine to incrementally dispense from the fluid cartridge 120. Power signals, such as signals from a rechargeable battery (not shown) of the controller device 200 and from the power source 310 (refer to
As shown in
Still referring to
Accordingly, when the controller device 200 is connected to the pump device 100, the user can be provided with the opportunity to readily monitor the infusion pump operation by simply viewing the user interface 220 of the controller device 200 connected to the pump device 100. Such monitoring capabilities may provide comfort to a user who may have urgent questions about the current operation of the pump device 100. Also, in these embodiments, there may be no need for the user to carry and operate a separate module to monitor the operation of the pump device 100, thereby simplifying the monitoring process and reducing the number of devices that must be carried by the user. If a need arises in which the user desires to monitor the operation of the pump device 100 or to adjust the settings of the pump system 10 (e.g., to request a bolus amount of medicine), the user can readily operate the user interface 220 of the controller device 200, which is removably attached to the pump device 100, without the requirement of locating and operating a separate monitoring module.
The controller device 200 can also be equipped with an inspection light device 230. The inspection light device 230 can provide the user with a tool to illuminate and inspect a targeted location. For example, the inspection light device 230 can be directed at the infusion site on the user's skin to verify that the infusion set is properly embedded, or the inspection light device 230 can be directed at the pump device 100 to illuminate the cavity 116 or other areas. The inspection light device 230 can also be used to notify the user to an alert condition of the pump system 10. An activation of the inspection light device 230 can thereby provide a visual notification (as an alternative to, or in addition to, the visual notification provided on the display device 222) to the user that attention to the pump system 10 is warranted.
When the infusion pump system 10 operates, the controller device 200 can be removably attached to the pump device 100 in a side-by-side arrangement. For example, the pump device 100 may be moved in a longitudinal direction toward the controller device 200 until the complementary features connect and secure the separate components in the side-by-side arrangement. The controller device 200 can include a controller housing 210 having a number of features that are configured to mate with complementary features of the pump housing 110 so as to form a releasable mechanical connection.
Referring to
In some embodiments, the infusion pump system 10 can be pocket-sized so that the pump device 100 and controller device 200 can be worn in the user's pocket or in another portion of the user's clothing. In some circumstances, the user may desire to wear the pump system 10 in a more discrete manner. Accordingly, the user can pass the tube 147 from the pocket, under the user's clothing, and to the infusion site where the adhesive patch can be positioned. As such, the pump system 10 can be used to deliver medicine to the tissues or vasculature of the user in a portable, concealable, and discrete manner.
In some embodiments, the infusion pump system 10 can be configured to adhere to the user's skin directly at the location in which the skin is penetrated for medicine infusion. For example, a rear surface of the pump device 100 can include a skin adhesive patch so that the pump device 100 can be physically adhered to the skin of the user at a particular location. In these embodiments, the cap device 130 can have a configuration in which medicine passes directly from the cap device 130 into an infusion cannula 149 that is penetrated into the user's skin. In some examples, the user can temporarily detach the controller device 200 (while the pump device 100 remains adhered to the skin) so as to view and interact with the user interface 220.
Referring now to
In this embodiment, the housing 110 of pump device 100 carries the drive system 300 and the power source 310. For example, the power source 310 may comprise an alkaline battery cell, such as a 1.5 Volt “AAA” alkaline battery cell, which is contained in a dedicated space of the pump housing 110. The power source 310 may be capable of transmitting electrical energy to the controller device 200 when the pump device 100 is attached to the controller device 200, via connectors 118 and 218 as described above. For example, the power source 310 may be used to charge the rechargeable battery pack of the controller device 200 when the pump device 100 is attached to the controller device 200. In some embodiments, the power source 310 is used to provide energy to the drive system 300 of the pump device 100 (in response to control signals from the controller device 200), and also to electronic components of the controller device 200. In particular embodiments, the power source 310 may provide the energy to power all aspects of the infusion pump system 10. In some alternative embodiments, the rechargeable battery housed in the controller device 200 may provide the energy to power all aspects of the infusion pump system 10. In other embodiments, the rechargeable battery of the controller device 200 and the power source 310 may each be responsible for powering particular aspects of the infusion pump system 10. In further embodiments, the rechargeable battery may provide the energy to supplement the energy provided by the power source 310 to power aspects of the infusion pump system.
Still referring to
The flexible piston rod 370 can be incrementally advanced forward (toward the fluid cartridge 120) so as to dispense the medicine from the pump device 100 by pressing against the plunger 125. The force from the piston rod 370 overcomes a frictional “glide force” of the plunger 125 to advance the plunger 125 through the fluid cartridge 120 to dispense medicine. In this embodiment, the reversible motor 320 drives a gear system (not shown in
Referring now to
Under certain circumstances, other stresses exerted on the plunger 125 may overcome the retention force of the penetration members 436, causing the plunger 125 to not fully seat against the forward face of the piston rod 370 (e.g., the face of a pusher block 413 as shown in
As previously described, the gap between the plunger 125 and the piston hub 404 may cause dosage inaccuracies during operation of the pump device 100. For example, the piston rod 370 may be driven forward through a longitudinal distance equal to the size of the gap before the piston hub 404 contacts the plunger 125 to push the plunger 125 through the fluid cartridge 120. In this case, the piston rod 370 moves a greater distance through the fluid cartridge 120 than the plunger 125, which may result in an inaccurate dispensation of medicine (an under-dosage in this particular example).
An inaccurate dosage of medicine (e.g., more or less medicine than the dosage determined by the controller device 200) may be dispensed if the movement of the plunger 125 does not closely match the incremental movement to the piston rod 370. As noted above, in this embodiment, the incremental motion of the piston rod 370 and plunger 125 required to dispense an appropriate dose of medicine from the fluid cartridge 120 may be 16 microns or less. Therefore, a small gap between the between the rearward face of the plunger 125 and the forward face of the piston rod (even a gap as small as about 6 microns to about 8 microns) could potentially cause a dosage inaccuracy along the order of one or more dispensation cycles of the drive system. Thus, in some embodiments, the plunger engagement device 400 is provided with a retention spring 406 (
As shown in
The bore 414 is shaped to receive a threaded forward end 376 of the piston rod 370 (
The base 410 radially surrounds the frame 412 to provide a flange including a plurality of radial spokes 426. The spokes 426 are spaced apart from one another and distributed circumferentially around the base 410. The spring hub 408 is attached to the undersurface the base 410 and includes a plurality of radial tabs 428 protruding through the spaces between neighboring spokes 426. In this embodiment, the piston hub 404 includes six spokes 426 and the spring hub 408 includes six tabs 428. However, other suitable configurations are also contemplated within the scope of this document. The tabs 428 of the spring hub 408 extend obliquely outward along a curved upslope to meet the inner wall of the fluid cartridge 120. The tabs 428 are both flexible and resilient, and therefore bear against the inner wall of the cartridge 120. Thus, the tabs 428 provide substantial frictional forces that resist movement of the spring hub 408 (and therefore the attached piston hub 404) rearward relative to the fluid cartridge 120. However, the curved upsloping shape and orientation of the tabs 428 causes the tabs 428 to flex inward when the spring hub 408 (and therefore the attached piston hub 404) is forced forward relative to the fluid cartridge 120 (e.g., in response a force provided by the piston rod 370, or the force 140).
Referring to
Each of the struts 433 includes a latch member 434 and a penetration member 436. The latch member 434 includes a catch member 440 and a finger flange 442. With the retention plate 402 installed on the piston hub 404, the latch member 434 of each strut 433 is located in a respective slot 425 of the piston hub 404. In this position, the catch member 440 and the finger flange 442 are slidingly engaged with the side wall 422 and the platform 418 of the piston hub 404, with the finger flange 442 seated against the end wall 424 and the catch member 440 located beneath the arm member 420. Each of the penetration members 436 includes an elongated shank 446 projecting through a respective opening 421 of the piston hub 404 (and the spring hub 408) to terminate in a distal tip 448. As noted above, the penetration member 436 are configured (e.g., appropriately sized, shaped, and otherwise fabricated) to couple the plunger 125 to the piston rod 370 during operation of the pump device 100. The penetration members 436 may extend to a total length (including the shank 446 and the tip 448) that is slightly less than the axial length of the plunger 125. In such circumstances, the penetration members 436 do not penetrate through the front face (e.g., the “wet” face) of the plunger 125 (
In this embodiment, each of the distal tips 448 of the respective penetration members 436 is provided in the form of an arrow shaped member including a pointed head 450 and opposing angled-cut retention barbs 452. The pointed head 450 of the tip 448 may facilitate penetration into the rear face of the plunger 125 (e.g., the “dry” face of the plunger 125 opposite the “wet” face). The retention barbs 452 of the tip 448 may enhance the engagement between the penetration member 436 and the plunger 125, thereby increasing a retention force that resists relative longitudinal movement between the plunger 125 and the penetration members 436.
It should be understood from the description herein that, in other embodiments, the penetration members 436 may have a different configuration. For example, in some embodiments, suitable penetration members may be provided in the form of pin inserts. Such penetration members can include a generally straight shank and pointed tip to facilitate penetration into the rear face of the plunger. In some embodiments, suitable penetration members can be provided in the form of radially curved blades. Such embodiments of the penetration members may include generally flat blade shanks that are curved about a longitudinal axis. In some embodiments, the retention barbs can be straight-cut portions. In some embodiments, the pointed head of at the tip of the penetration member can include one or more serrations or other retention features to increase the retention force. Penetration members with different configurations may provide varying amounts of retention force.
In some embodiments, the penetration members 436 can reduce the compliance of the plunger material and thereby increase the dosage accuracy. For example, the plunger 125 may comprise an elastomer material that exhibits flexibility and compliance when it is urged longitudinally relative to the inner wall of the fluid cartridge 120 (e.g., the center of the plunger is urged forward while the outer radial surfaces flex due to the frictional engagement with the inner wall of the fluid cartridge). Such compliance may create a level of unpredictability between the piston rod movement and the corresponding plunger movement. The penetration members 436 can pierce into the plunger 125 and thereby serve as generally rigid inserts that reduce the compliance exhibited by the plunger 125. In some circumstances, the penetration members 436 can serve as inserts that provide greater uniformity between the piston rod movement and the corresponding plunger movement. As such, the pump device 100 may have increased accuracy for the dosage of medicine that is dispensed in response to an incremental movement of the piston rod 370. In this embodiment, the retention plate 402 includes two penetration members 436 that are laterally offset from the center plunger 125, so as to pierce the rear face of the plunger 125 in an outer radial portion of the plunger 125 (e.g., a portion of the plunger that might otherwise be more compliant during advancement of the plunger 125 inside the fluid cartridge 120).
Referring back to
Referring to
As shown in
As shown in
Referring now to
Similar to previously described embodiments of the plunger engagement device 400 (
Still referring to
Accordingly, the user may press one or more of the buttons 924a, 924b, 924c, 924d, and 924e to shuffle through a number of menus or program screens that show particular settings and data (e.g., review data that shows the medicine dispensing rate, the total amount of medicine dispensed in a given time period, the amount of medicine scheduled to be dispensed at a particular time or date, the approximate amount of medicine remaining in the fluid cartridge 120, or the like). Also, the user can adjust the settings or otherwise program the pump system 900 by pressing one or more buttons 924a, 924b, 924c, 924d, and 924e of the user interface 920. Thus, the user can contemporaneously monitor the operation of the pump system 900 from the same user interface 920.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
Number | Name | Date | Kind |
---|---|---|---|
4373527 | Fischell | Feb 1983 | A |
4652260 | Fenton et al. | Mar 1987 | A |
4668220 | Hawrylenko | May 1987 | A |
4902278 | Maget et al. | Feb 1990 | A |
5062830 | Dunlap | Nov 1991 | A |
5176632 | Bernardi | Jan 1993 | A |
5637095 | Nason et al. | Jun 1997 | A |
5672167 | Athayde et al. | Sep 1997 | A |
5718562 | Lawless | Feb 1998 | A |
5800420 | Grose et al. | Sep 1998 | A |
6106498 | Friedli | Aug 2000 | A |
6127061 | Shun et al. | Oct 2000 | A |
6231540 | Smedegaard | May 2001 | B1 |
6248067 | Causey, III et al. | Jun 2001 | B1 |
6248090 | Jensen et al. | Jun 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6277098 | Klitmose et al. | Aug 2001 | B1 |
6302855 | Lav et al. | Oct 2001 | B1 |
6302869 | Klitgaard | Oct 2001 | B1 |
6375638 | Nason et al. | Apr 2002 | B2 |
6379339 | Klitgaard et al. | Apr 2002 | B1 |
6381496 | Meadows et al. | Apr 2002 | B1 |
6404098 | Kayama et al. | Jun 2002 | B1 |
6427088 | Bowman, IV et al. | Jul 2002 | B1 |
6461331 | Van Antwerp | Oct 2002 | B1 |
6474219 | Klitmose et al. | Nov 2002 | B2 |
6485461 | Mason et al. | Nov 2002 | B1 |
6491684 | Joshi et al. | Dec 2002 | B1 |
6508788 | Preuthun | Jan 2003 | B2 |
6524280 | Hansen et al. | Feb 2003 | B2 |
6533183 | Aasmul et al. | Mar 2003 | B2 |
6537251 | Klitmose | Mar 2003 | B2 |
6537268 | Gibson et al. | Mar 2003 | B1 |
6540672 | Simonsen et al. | Apr 2003 | B1 |
6544229 | Danby et al. | Apr 2003 | B1 |
6547764 | Larsen et al. | Apr 2003 | B2 |
6551276 | Mann et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6554800 | Nezhadian et al. | Apr 2003 | B1 |
6558320 | Causey, III et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6562001 | Lebel et al. | May 2003 | B2 |
6562011 | Buch-Rasmussen et al. | May 2003 | B1 |
6564105 | Starkweather et al. | May 2003 | B2 |
6569126 | Poulsen et al. | May 2003 | B1 |
6571128 | Lebel et al. | May 2003 | B2 |
6577899 | Lebel et al. | Jun 2003 | B2 |
6582404 | Klitgaard et al. | Jun 2003 | B1 |
6585644 | Lebel et al. | Jul 2003 | B2 |
6585699 | Ljunggreen et al. | Jul 2003 | B2 |
6605067 | Larsen | Aug 2003 | B1 |
6613019 | Munk | Sep 2003 | B2 |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6648821 | Lebel et al. | Nov 2003 | B2 |
6650951 | Jones et al. | Nov 2003 | B1 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6659948 | Lebel et al. | Dec 2003 | B2 |
6659978 | Kasuga et al. | Dec 2003 | B1 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6663602 | Møller | Dec 2003 | B2 |
6668196 | Villegas et al. | Dec 2003 | B1 |
6669668 | Kleeman et al. | Dec 2003 | B1 |
6669669 | Flaherty et al. | Dec 2003 | B2 |
6687546 | Lebel et al. | Feb 2004 | B2 |
6690192 | Wing | Feb 2004 | B1 |
6691043 | Ribeiro, Jr. | Feb 2004 | B2 |
6692457 | Flaherty | Feb 2004 | B2 |
6692472 | Hansen et al. | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6702779 | Connelly et al. | Mar 2004 | B2 |
6715516 | Ohms et al. | Apr 2004 | B2 |
6716198 | Larsen | Apr 2004 | B2 |
6723072 | Flaherty et al. | Apr 2004 | B2 |
6733446 | Lebel et al. | May 2004 | B2 |
6736796 | Shekalim | May 2004 | B2 |
6740059 | Flaherty | May 2004 | B2 |
6740072 | Starkweather et al. | May 2004 | B2 |
6740075 | Lebel et al. | May 2004 | B2 |
6744350 | Blomquist | Jun 2004 | B2 |
6749587 | Flaherty | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6758810 | Lebel et al. | Jul 2004 | B2 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6780156 | Haueter et al. | Aug 2004 | B2 |
6786246 | Ohms et al. | Sep 2004 | B2 |
6786890 | Preuthun et al. | Sep 2004 | B2 |
6796957 | Carpenter et al. | Sep 2004 | B2 |
6796970 | Klitmose et al. | Sep 2004 | B1 |
6799149 | Hartlaub | Sep 2004 | B2 |
6809653 | Mann et al. | Oct 2004 | B1 |
6810290 | Lebel et al. | Oct 2004 | B2 |
6811533 | Lebel et al. | Nov 2004 | B2 |
6811534 | Bowman, IV et al. | Nov 2004 | B2 |
6813519 | Lebel et al. | Nov 2004 | B2 |
6827702 | Lebel et al. | Dec 2004 | B2 |
6830558 | Flaherty et al. | Dec 2004 | B2 |
6852104 | Blomquist | Feb 2005 | B2 |
6854620 | Ramey | Feb 2005 | B2 |
6854653 | Eilersen | Feb 2005 | B2 |
6855129 | Jensen et al. | Feb 2005 | B2 |
6872200 | Mann et al. | Mar 2005 | B2 |
6873268 | Lebel et al. | Mar 2005 | B2 |
6878132 | Kipfer | Apr 2005 | B2 |
6893415 | Madsen et al. | May 2005 | B2 |
6899695 | Herrera | May 2005 | B2 |
6899699 | Enggaard | May 2005 | B2 |
6922590 | Whitehurst | Jul 2005 | B1 |
6936006 | Sabra | Aug 2005 | B2 |
6936029 | Mann et al. | Aug 2005 | B2 |
6936032 | Bush et al. | Aug 2005 | B1 |
6945961 | Miller et al. | Sep 2005 | B2 |
6948918 | Hansen | Sep 2005 | B2 |
6950708 | Bowman, IV et al. | Sep 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6979326 | Mann et al. | Dec 2005 | B2 |
6997911 | Klitmose | Feb 2006 | B2 |
6997920 | Mann et al. | Feb 2006 | B2 |
7005078 | Van Lintel et al. | Feb 2006 | B2 |
7008399 | Larson et al. | Mar 2006 | B2 |
7014625 | Bengtsson | Mar 2006 | B2 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7025743 | Mann | Apr 2006 | B2 |
7029455 | Flaherty | Apr 2006 | B2 |
7054836 | Christensen et al. | May 2006 | B2 |
7104972 | Møller et al. | Sep 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7133329 | Skyggebjerg et al. | Nov 2006 | B2 |
7172572 | Diamond et al. | Feb 2007 | B2 |
7232423 | Mernoe et al. | Jun 2007 | B2 |
7597682 | Moberg | Oct 2009 | B2 |
7654982 | Carlisle et al. | Feb 2010 | B2 |
7875022 | Wenger et al. | Jan 2011 | B2 |
20010041869 | Causey, III et al. | Nov 2001 | A1 |
20010056262 | Cabiri | Dec 2001 | A1 |
20020004651 | Ljndggreen et al. | Jan 2002 | A1 |
20020007154 | Hansen et al. | Jan 2002 | A1 |
20020016568 | Lebel | Feb 2002 | A1 |
20020032402 | Daoud et al. | Mar 2002 | A1 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20020091358 | Klitmose | Jul 2002 | A1 |
20020126036 | Flaherty et al. | Sep 2002 | A1 |
20020156462 | Stultz | Oct 2002 | A1 |
20030055380 | Flaherty | Mar 2003 | A1 |
20030065308 | Lebel et al. | Apr 2003 | A1 |
20030088238 | Poulsen | May 2003 | A1 |
20030105430 | Lavi | Jun 2003 | A1 |
20030125672 | Adair et al. | Jul 2003 | A1 |
20030161744 | Vilks et al. | Aug 2003 | A1 |
20030199825 | Flaherty | Oct 2003 | A1 |
20030216683 | Shekalim | Nov 2003 | A1 |
20030216686 | Lynch et al. | Nov 2003 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040019325 | Shekalim | Jan 2004 | A1 |
20040064088 | Gorman et al. | Apr 2004 | A1 |
20040064096 | Flaherty et al. | Apr 2004 | A1 |
20040078028 | Flaherty et al. | Apr 2004 | A1 |
20040087894 | Flaherty | May 2004 | A1 |
20040092865 | Flaherty et al. | May 2004 | A1 |
20040092878 | Flaherty | May 2004 | A1 |
20040115068 | Hansen et al. | Jun 2004 | A1 |
20040116866 | Gorman et al. | Jun 2004 | A1 |
20040127844 | Flaherty | Jul 2004 | A1 |
20040153032 | Garnbotto et al. | Aug 2004 | A1 |
20040171983 | Sparks et al. | Sep 2004 | A1 |
20040176727 | Shekalim | Sep 2004 | A1 |
20040187952 | Jones | Sep 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040204744 | Penner et al. | Oct 2004 | A1 |
20040220551 | Flaherty et al. | Nov 2004 | A1 |
20040235446 | Flaherty et al. | Nov 2004 | A1 |
20040260233 | Garibotto et al. | Dec 2004 | A1 |
20050021005 | Flaherty et al. | Jan 2005 | A1 |
20050022274 | Campbell et al. | Jan 2005 | A1 |
20050038332 | Saidara et al. | Feb 2005 | A1 |
20050065760 | Murtfeldt et al. | Mar 2005 | A1 |
20050090808 | Malave et al. | Apr 2005 | A1 |
20050095063 | Fathallah | May 2005 | A1 |
20050113745 | Stultz | May 2005 | A1 |
20050124866 | Elaz et al. | Jun 2005 | A1 |
20050160858 | Mernoe | Jul 2005 | A1 |
20050171476 | Judson | Aug 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050182366 | Vogt et al. | Aug 2005 | A1 |
20050192561 | Mernoe | Sep 2005 | A1 |
20050203461 | Flaherty et al. | Sep 2005 | A1 |
20050215982 | Malave et al. | Sep 2005 | A1 |
20050222645 | Malave et al. | Oct 2005 | A1 |
20050238507 | Dilanni et al. | Oct 2005 | A1 |
20050245878 | Mernoe et al. | Nov 2005 | A1 |
20050251097 | Mernoe | Nov 2005 | A1 |
20050267402 | Stewart et al. | Dec 2005 | A1 |
20050273059 | Mernoe et al. | Dec 2005 | A1 |
20060041229 | Garibotto et al. | Feb 2006 | A1 |
20060069382 | Pedersen | Mar 2006 | A1 |
20060074381 | Malave et al. | Apr 2006 | A1 |
20060095014 | Ethelfeld | May 2006 | A1 |
20060135913 | Ethelfeld | Jun 2006 | A1 |
20060142698 | Ethelfeld | Jun 2006 | A1 |
20060151545 | Imhof | Jul 2006 | A1 |
20060178633 | Garibotto et al. | Aug 2006 | A1 |
20060184119 | Remde et al. | Aug 2006 | A1 |
20060200073 | Radmer et al. | Sep 2006 | A1 |
20060206054 | Shekalim | Sep 2006 | A1 |
20060247581 | Pedersen et al. | Nov 2006 | A1 |
20060247582 | Alheidt | Nov 2006 | A1 |
20070073228 | Mernoe et al. | Mar 2007 | A1 |
20070073236 | Mernoe et al. | Mar 2007 | A1 |
20070088271 | Richards | Apr 2007 | A1 |
20070093750 | Jan et al. | Apr 2007 | A1 |
20070106218 | Yodfat et al. | May 2007 | A1 |
20070124002 | Estes et al. | May 2007 | A1 |
20070156092 | Estes et al. | Jul 2007 | A1 |
20070167905 | Estes et al. | Jul 2007 | A1 |
20070167912 | Causey | Jul 2007 | A1 |
20070197968 | Pongpairochana | Aug 2007 | A1 |
20070251097 | Terry | Nov 2007 | A1 |
20080009824 | Moberg et al. | Jan 2008 | A1 |
20080208627 | Skyggebjerg | Aug 2008 | A1 |
20080294094 | Mhatre | Nov 2008 | A1 |
20080294142 | Patel | Nov 2008 | A1 |
20090318878 | Chavez | Dec 2009 | A1 |
20100325864 | Briones et al. | Dec 2010 | A1 |
20120078170 | Smith et al. | Mar 2012 | A1 |
20120330270 | Colton | Dec 2012 | A1 |
20130046276 | Mernoe | Feb 2013 | A1 |
20140121633 | Causey et al. | May 2014 | A1 |
Number | Date | Country |
---|---|---|
2543545 | May 2005 | CA |
196 27 619 | Jan 1998 | DE |
102 36 669 | Feb 2004 | DE |
0 062 974 | Oct 1982 | EP |
0 275 213 | Jul 1988 | EP |
0 496 141 | Jul 1992 | EP |
0 612 004 | Aug 1994 | EP |
0 580 723 | Oct 1995 | EP |
1 045 146 | Oct 2000 | EP |
1 136 698 | Sep 2001 | EP |
1 177 802 | Feb 2002 | EP |
0 721 358 | May 2002 | EP |
1 495 775 | Jan 2005 | EP |
1 527 792 | May 2005 | EP |
1 754 498 | Feb 2007 | EP |
1 818 664 | Aug 2007 | EP |
2 585 252 | Jan 1987 | FR |
747 701 | Apr 1956 | GB |
2 218 831 | Nov 1989 | GB |
A 9-504974 | May 1997 | JP |
2000-513974 | Oct 2000 | JP |
2002-507459 | Mar 2002 | JP |
A 2002-523149 | Jul 2002 | JP |
WO 9015928 | Dec 1990 | WO |
WO 9721457 | Jun 1997 | WO |
WO 199804301 | Feb 1998 | WO |
WO 9811927 | Mar 1998 | WO |
WO 9857683 | Dec 1998 | WO |
WO 9921596 | May 1999 | WO |
WO 9939118 | Aug 1999 | WO |
WO 9948546 | Sep 1999 | WO |
WO 2001054753 | Aug 2001 | WO |
WO 200172360 | Oct 2001 | WO |
WO 200191822 | Dec 2001 | WO |
WO 200191833 | Dec 2001 | WO |
WO 200240083 | May 2002 | WO |
WO 2002057627 | Jul 2002 | WO |
WO 2002068015 | Sep 2002 | WO |
WO 2002084336 | Oct 2002 | WO |
WO 2002100469 | Dec 2002 | WO |
WO 2003026726 | Apr 2003 | WO |
WO 2003103763 | Dec 2003 | WO |
WO 2004056412 | Jul 2004 | WO |
WO 2004110526 | Dec 2004 | WO |
WO 2005002652 | Jan 2005 | WO |
WO 2005039673 | May 2005 | WO |
WO 2005072794 | Aug 2005 | WO |
WO 2005072795 | Aug 2005 | WO |
WO 2006067217 | Jun 2006 | WO |
WO 2006097453 | Sep 2006 | WO |
WO 2006105792 | Oct 2006 | WO |
WO 2006105793 | Oct 2006 | WO |
WO 2006105794 | Oct 2006 | WO |
Entry |
---|
International Search Report and Written Opinion in International Application No. PCT/US2015/46763, dated Jan. 11, 2016, 8 pages. |
Accu-Chek Spirit, “Pump Therapy Made for You,” Roche, 2006, 6 pages. |
Asante Solutions Pearl User Manual, Asante Inc., 2012, 180 pages. |
Collins and Lee, “Microfluidic flow transducer based on the measurement of electrical admittance,” Lab Chip, 2004 4 pages. |
Debiotech News Release, “Debiotech reveals its new miniaturized Disposable Insulin Nanopump™ for Diabetes therapy,” available at http://www.debiotech.com/news/nw_159.html Apr. 24, 2006, 3 pages. |
Medtronic News Release, “Medtronic Receives FDA Approval for World's First Insulin Pump with Real-time Continuous Glucose Monitoring,” Apr. 13, 2006, 3 pages. |
OmniPod Insulin Management System-Investor Relations—Press Release, Feb. 1, 2005, http://investors.insulet.com/phoenix.zhtml?c=209336&p=iro-newsArticleID=9887088&highlight= 1 page. |
OmniPod Quick Start Guide, 2007, 2 pages. |
Patent Abstracts of Japan, vol. 1999, No. 04, and JP 11 010036 , Apr. 30, 1999 and Jan. 19, 1999, Toray Ind. Inc. |
The Medtronic Diabetes Connection, 2006, 6 pages. |
Xilas Temp Touch, “The latest in high-tech and convenient devices,” DOCNews, vol. 2, No. 7, Jul. 1, 2005, http://docnews.diabetesjournals.ord/cgi/content/full/2/7/13, 3 pages. |
Number | Date | Country | |
---|---|---|---|
20160058939 A1 | Mar 2016 | US |